Andrea Small-Howard

Andrea Small-Howard

Company: GB Sciences

Job title: Chief Science Officer


Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc. Dr. Small-Howard has more than 15 years’ experience studying cannabinoids and the endocannabinoid system, immunology and cancer treatments; as well as executive experience in the biopharmaceutical industry where she supervised research and development, manufacturing and quality control divisions. She took the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration (“US FDA”) and multiple international regulatory agencies, and has assisted state jurisdictions in developing medical cannabis regulations. She brings to GB Sciences a passion for advancing clinical research on medicinal applications of cannabinoid compounds in cannabis plants, clinical experience in conducting cannabinoid research, strategic vision for creating a vertically integrated biopharmaceutical pipeline, and a track record of successes in the management of biopharmaceutical companies.


Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), in addition to receiving both an MBA (Beta Gamma Sigma) and a PhD (USC All-University Merit Fellow) in biological sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard led a project group dedicated to the study of cannabinoids in the immune system and published peer-reviewed papers on the subject. At the John A. Bums School of Medicine – University of Hawaii, she led a productive research team as a Research Assistant Professor. Dr. Small-Howard has held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp. (RPC), she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. At RPC, she also played an active role in creating collaboration agreements with development partners and research institutions, and she contributed to critical licensing and distribution agreements. For a four year term, she served on the Board of Directors for the Center for Healthcare Innovation, a nonprofit, non-partisan, and independent organization based in Chicago that is committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation.


Unique Methods to Identify Strong Lead Compounds 9:00 am

• Understand lead identification strategy • Explore different methodologies and their effectiveness in the cannabinoid research fieldRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.